The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
CULLIN3-based E3 ubiquitin ligase substrate-binding adaptor gene SPOP is frequently mutated in prostate cancer (PCa). PCa harboring SPOP hotspot mutants (e.g., F133V) are resistant to BET inhibitors because of aberrant elevation of BET proteins. Here, we identified a previously unrecognized mutation Q165P at the edge of SPOP MATH domain in primary and metastatic PCa of a patient. The Q165P mutation causes structural changes in the MATH domain and impairs SPOP dimerization and substrate degradation. Different from F133V hotspot mutant tumors, Q165P mutant patient-derived xenografts (PDXs) and organoids were modestly sensitive to the BET inhibitor JQ1. Accordingly, protein levels of AR, BRD4 and downstream effectors such as RAC1 and phosphorylated AKT were not robustly elevated in Q165P mutant cells as in F133V mutant cells. However, NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo. These data provide a strong rationale to clinically investigate the anti-cancer efficacy of NEO2734 in SPOP-mutated PCa patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationModeling of loops in protein structures
Fiser, A., Do, R. K. G., & Šali, A. (2000) · Protein Science · doi:10.1110/ps.9.9.1753 · Cited by 2,116 · cited 1×
“The missing loops in the crystal structure of SPOP dimer (3HQI.pdb residue 24–331) were built by Modeller (Fiser et al, 2000).”
MethodOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationDiscovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
Zhuang, M., Calabrese, M. F., Liu, J., Waddell, M. B., Nourse, A., Hammel, M., Miller, D. J., Walden, H., Duda, D. M., Seyedin, S. N., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.022 · Cited by 486 · cited 6×
“%) detected thus far are missense heterozygous mutations that are located in the MATH domain (Cancer Genome Atlas Research Network, 2015; Armenia et al, 2018), a motif responsible for substrate recognition and interaction (Zhuang et al, 2009; Fig 1C).”
BackgroundInfluentialBlattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204 · cited 4×
“Both AR and AKT signaling pathways are highly activated in SPOP mutant PCa (An et al, 2014; Geng et al, 2014; Blattner et al, 2017; Zhang et al, 2017).”
BackgroundResultInfluentialSelf-citationSPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Boysen, G., Rodrigues, D. N., Rescigno, P., Seed, G., Dolling, D., Riisnaes, R., Crespo, M., Zafeiriou, Z., Sumanasuriya, S., Bianchini, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0937 · Cited by 145 · cited 1×
“…among different subtypes of PCa (Cancer Genome Atlas Research Network, 2015), SPOP-mutated PCa cells are highly sensitive to treatment of androgen inhibitory agent abiraterone when SPOP mutation is co-occurred with CHD1 deletion (Boysen et al, 2018), supporting the notion of oncogene addiction.”
BackgroundYan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708478 · Cited by 53
Self-citation
Cited by
Achieving clinical success with BET inhibitors as anti-cancer agents
Shorstova, T., Foulkes, W. D., & Witcher, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01321-0 · Cited by 347
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 275
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
“Unlike F133V hotspot mutant tumors, patient‐derived xenografts (PDXs) and organoids with Q165P mutation are modestly sensitive to BET inhibitor JQ1.(154) Importantly, NEO2734 is active in”
BackgroundSelf-citationAcetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Metadata
- Authors
- Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., Zhang, J., Wahlestedt, C., Giles, F. J., Chen, Y., Gleave, M. E., Collins, C. C., Ye, D., Wang, Y., & Huang, H.
- Venue
- EMBO Molecular Medicine
- Published
- 2019-09-26
- Volume
- 11
- Issue
- 11
- Pages
- e10659-e10659
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2976879024
- Cited by
- 92
- References
- 8
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer. https://app.cochat.ai/papers/10.15252/emmm.201910659
- The paper
- Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., Zhang, J., Wahlestedt, C., Giles, F. J., Chen, Y., Gleave, M. E., Collins, C. C., Ye, D., Wang, Y., & Huang, H. (2019). The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201910659
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.